Workflow
润都股份(002923) - 2019 Q1 - 季度财报
Rundu PharmaRundu Pharma(SZ:002923)2019-04-22 16:00

Financial Performance - The company's revenue for Q1 2019 was CNY 340,703,319.84, representing a 53.35% increase compared to CNY 222,172,370.14 in the same period last year[7] - Net profit attributable to shareholders was CNY 28,986,836.25, up 45.23% from CNY 19,959,945.38 year-on-year[7] - Basic and diluted earnings per share rose by 9.09% to CNY 0.24 from CNY 0.22 in the same period last year[7] - Total revenue for Q1 2019 reached ¥340.70 million, a 53.35% increase compared to ¥222.17 million in Q1 2018, primarily due to expanded sales scale[17] - The company reported a total comprehensive income for the period of CNY 28,986,836.25, compared to CNY 19,959,945.38 in the previous year, showing overall financial growth[42] Cash Flow - The net cash flow from operating activities increased by 140.12% to CNY 46,113,250.90, compared to CNY 19,204,268.11 in the previous year[7] - Cash inflows from operating activities totaled CNY 290,526,021.05, indicating strong sales performance[50] - The company reported a net cash outflow from investing activities of CNY 39,048,197.18, reflecting ongoing investments in growth initiatives[50] - Total cash inflow from operating activities was CNY 177,944,666.28, up from CNY 117,940,753.81, marking an increase of approximately 51%[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,224,803,039.44, a 7.59% increase from CNY 1,138,419,861.16 at the end of the previous year[7] - The total liabilities of the company were CNY 324,521,650.99, up from CNY 267,125,308.96, which is an increase of approximately 21.43%[32] - The company's current assets totaled CNY 830,075,269.77, up from CNY 774,755,173.40 at the end of 2018, indicating an increase of about 7.13%[31] Expenses - Operating costs increased by 43.91% to ¥96.56 million from ¥67.10 million, attributed to the growth in sales[17] - R&D expenses surged by 226.06% to ¥34.76 million from ¥10.66 million, reflecting increased investment in research and development[17] - Sales expenses increased by 62.86% to ¥165.04 million from ¥101.34 million, due to higher marketing and academic promotion costs[17] - Management expenses decreased by 40.88% to ¥10.77 million from ¥18.21 million, as last year's figures included significant listing expenses[17] Accounts Receivable and Payable - Accounts receivable increased by 30.54% to CNY 168,528,511.38, primarily due to expanded sales[16] - The company reported a 115.94% increase in accounts payable, reaching CNY 40,703,859.71, also due to business expansion[16] - Other payables rose by 87.81% to CNY 130,170,455.93, driven by increased market development and academic promotion expenses[16] Investment Activities - Investment cash flow net amount decreased by 74.79% to -¥39.05 million from -¥22.34 million, mainly due to increased fixed asset investments[19] - The company received CNY 291,000,000.00 from investment recoveries, indicating strong cash inflow from investment activities[52] Equity - The company's equity remained stable at CNY 120,000,000.00, unchanged from the previous reporting period[32] - The company's total equity attributable to shareholders reached ¥897,963,489.46, compared to ¥874,912,175.48 at the end of 2018, reflecting a growth of 2.6%[38]